NK Cell Therapies for Cancer
Also Clin0 Hodgkin's lymphoma/T-cell lymphoma, Clin0 multiple myeloma; AB-201 Clin1 HER2+ cancers; AB-203 RD/Cln0 multiple myeloma; AB-205 RD/Clin0 T-cell lymphoma; AB-MK-001 RD/Clin0 solid tumor; AB-MK-002 RD/Clin0 solid tumor
Artiva Biotherapeutics is developing immune cell therapies to treat cancer. Natural killer (NK) cells are part of the innate immune system that are the first line of defense for the recognition and destruction of cancerous cells. Artiva is engineering NK cells using their AlloNKTM platform to enhance their targeting and activity. Specifically, Artiva is focused on generating off-the-shelf, allogeneic NK cell therapies with improved performance to treat hematologic cancers or solid tumors. The platform is designed to deliver scalability, quality and cryopreservation to support their mission of creating a pipeline of safe, effective, versatile and accessible products. Artiva’s lead program is in Phase 1 trials for B-cell malignancies.
San Diego, California|16 days ago
Associate Manager, Clinical Logistics
San Diego, California|47 days ago
Sr. Associate, Quality Control (Environmental Moni...
San Diego, California|70 days ago
Manager, Quality Control, Raw Materials
San Diego, California|71 days ago
Senior Manager, Clinical Data Management
San Diego, California|95 days ago
Sr. Clinical Trials Manager
San Diego, California|100+ days ago